Key PointsQuestion
Are people with rheumatoid arthritis (RA) at increased risk of developing aortic stenosis (AS)?
Findings
In this cohort study of 73 070 patients with RA who were matched with 639 268 patients without RA, those with RA had an increased risk of developing AS, undergoing aortic valve intervention, and AS-related death.
Meaning
Findings of this study suggest that RA is associated with a higher risk of developing AS as well as the subsequent risks of aortic valve intervention and AS-related death.
Importance
Although an increased risk of ischemic cardiovascular disease has been associated with rheumatoid arthritis (RA), the risk of aortic stenosis (AS) is unknown.
Objective
To examine the risk of incident AS, aortic valve intervention, AS-related death, and risk factors for AS development in patients with RA.
Design, Setting, and Participants
This cohort study linked data from the Veterans Health Administration (VHA) and Centers for Medicare & Medicaid Services from 2000 to 2019. Patients with RA were matched by age, sex, and VHA enrollment year with up to 10 patients without RA. The cohort was followed until incident AS, aortic valve intervention, or death. Data were analyzed from August 23, 2022, to March 3, 2023.
Exposures
the primary exposure was the presence of RA, defined using validated RA algorithms.
Main Outcomes and Measures
Aortic stenosis was defined as a composite of inpatient or outpatient diagnoses, surgical or transcatheter aortic valve replacement, or AS-related death using diagnostic and procedural codes. Risk of AS development was assessed with multivariable Cox proportional hazards models adjusted for race, ethnicity, smoking status, body mass index, rurality, comorbidities, and health care use.
Results
The cohort included 73 070 patients with RA (64 008 [87.6%] males; mean [SD] age, 63.0 [11.9] years) matched with 639 268 patients without RA (554 182 [86.7%] males; mean [SD] age, 61.9 [11.7] years) and 16 109 composite AS outcomes that occurred over 6 223 150 person-years. The AS incidence rate was 3.97 (95% CI, 3.81-4.13) per 1000 person-years in patients with RA and 2.45 (95% CI, 2.41-2.49) per 1000 person-years in the control patients (absolute difference, 1.52 per 1000 person-years). Rheumatoid arthritis was associated with an increased risk of composite AS (adjusted hazard ratio [AHR], 1.48; 95% CI, 1.41-1.55), aortic valve intervention (AHR, 1.34; 95% CI, 1.22-1.48), and AS-related death (AHR, 1.26; 95% CI, 1.04-1.54).
Conclusions and Relevance
In this cohort study, RA was associated with a higher risk of developing AS and the subsequent risks of undergoing aortic valve intervention and suffering from AS-related death. Future studies are needed to confirm whether valvular heart disease, specifically AS, may be an overlooked cardiovascular disease complication in RA.
Cardiovascular disease (CVD) is the most frequent cause of death and accounts for the largest proportion of excess mortality in patients with rheumatoid arthritis (RA).1,2 A substantial body of evidence supports an association between the inflammatory milieu of RA and CVD risk through oxidative stress, endothelial and lipoprotein dysfunction, and posttranslational modifications of peptides and subsequent immune responses.3 Although most studies examining these associations have focused on atherosclerotic heart disease and heart failure, preclinical studies have also reported on the development of valvular carditis in transgenic mice who develop autoantibody-mediated inflammatory arthritis similar to RA.4 Additionally, histopathologic analysis of aortic valves in patients without RA and in animal models suggests a pathogenic role of lipoprotein deposition and chronic inflammation in the development of calcific aortic stenosis (AS).5-7
In a recent analysis of temporal trends in RA-related cause-specific mortality risk from our research group, contemporary RA cohorts had a persistently increased risk of CVD-related mortality.8 This included a 75% increased risk of valvular heart disease–related death, the most overrepresented cause of CVD death in RA. However, valvular heart disease is rarely described as an extra-articular manifestation of RA, and investigations in RA have largely been limited to small echocardiographic studies describing the prevalence of valvular abnormalities without longitudinal outcomes.9-11 Aortic stenosis is the most common reason for valve replacement and the most frequent cause of valvular heart disease–related death in the US.12 Furthermore, previous case series in RA describe aortitis with adjacent aortic valvulitis and that the aortic valve was the most commonly afflicted valve in previous cross-sectional studies of patients with RA.9,11,13,14 In this study, we evaluated the risk of AS and AS-related outcomes in a large, national matched cohort of patients with RA vs patients without RA, testing the hypothesis that RA is associated with a higher risk of incident AS, aortic valve intervention, and AS-related death. Additionally, we examined risk factors for AS development in patients with RA.
We conducted a retrospective, matched cohort study leveraging national Veterans Health Administration (VHA) and Centers for Medicare & Medicaid Services (CMS) data between January 1, 2000, and December 31, 2019. The VHA is the largest integrated health system in the US with robust administrative and electronic health record data available within the Veterans Affairs (VA) Informatics and Computing Infrastructure.15 Linkage with CMS data facilitated capture of inpatient and outpatient claims for Medicare enrollees who obtained care outside of the VHA. The VA Nebraska-Western Iowa Health Care System Institutional Review Board approved this study and waived patient informed consent because there was no prospective data collection or patient contact. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
Patients with RA were identified by querying the VA Corporate Data Warehouse (CDW) using validated administrative algorithms requiring the presence of 2 or more diagnostic codes for RA, a rheumatologist diagnosis of RA, and either a positive test result for RA autoantibody (rheumatoid factor [RF] or anti–cyclic citrullinated protein [anti-CCP] antibody) or dispensation of a disease-modifying antirheumatic drug (DMARD).16 Patients with RA were subsequently matched with up to 10 patients without RA by birth year, sex, and year of enrollment into the VHA system. The cohort entry date was the date the RA algorithm was fulfilled (corresponding calendar date for patients without RA). Patients were excluded if they had 1 or more AS diagnostic code or procedural code for an aortic valve intervention prior to study entry.17 Patients were followed until the earliest of the composite AS outcome, death, or end of study period.
The primary outcome was incident AS, defined as a composite of inpatient or outpatient AS diagnosis, aortic valve intervention, or AS-related death. Secondary outcomes were the individual aortic valve interventions and AS-related death outcomes. Aortic stenosis outcomes were identified in VHA and CMS data using an administrative algorithm adapted from validated diagnostic and procedural codes.18-20 Inpatient AS was identified as a hospital discharge diagnosis using International Classification of Diseases, 9th Revision (ICD-9) and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes. Outpatient AS diagnosis required 2 or more ICD-9 or ICD-10 codes on separate dates plus a Current Procedural Terminology code for a transthoracic echocardiogram. The ICD-9 and ICD-10 procedure codes were used to identify aortic valve interventions, including surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR). Vital status (ie, date of death) was assessed through linkage with the National Death Index, defining AS-related death when an ICD-10 code for AS was listed as the underlying cause of death. Diagnostic and procedural codes for AS and aortic valve interventions are detailed in eTable 1 in Supplement 1.
Covariates and AS Risk Factors
Covariates were selected a priori and obtained from the CDW. Demographic characteristics, including age, sex, self-reported race and ethnicity, and urban-rural residency, were collected from VHA enrollment records. Race and ethnicity were included because these social constructs may influence the frequency of health care use and the likelihood of detecting the primary outcome. Body mass index (BMI) was categorized by World Health Organization cutoffs, using weight at the most recent VHA encounter preceding study entry and modal height, as previously described.21,22 Smoking status (current, former, or never) was identified using data from the electronic health record.23 Comorbidity burden was quantified using the Rheumatic Disease Comorbidity Index (RDCI), a validated index that includes lung disease, CVD (hypertension, myocardial infarction, stroke, or other CVD), diabetes, cancer, depression, fracture, and gastric disease.24 A higher score on the RDCI indicates greater comorbidity. These individual comorbidities were defined by 2 or more diagnostic codes on separate days prior to cohort entry. Although AS contributes to the other CVD category, patients with AS were excluded prior to RDCI assessment. Health care use was defined as the number of outpatient visits and hospitalizations in the year preceding the study entry date.
To examine AS risk factors among patients with RA, we extracted RA-related autoantibody test results (RF and anti-CCP) and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level measurements from the CDW. Values for ESR and CRP level were considered elevated if they exceeded the upper limit of normal per the conducting laboratory. Prescription fills of conventional synthetic DMARDs (csDMARDs), biologic and targeted synthetic DMARDs (b/tsDMARDs), and glucocorticoids at any time prior to cohort entry were defined using pharmacy records within the CDW.
Baseline characteristics were compared using descriptive statistics, and unadjusted incidence rates were estimated and stratified by RA status. Cox proportional hazards models, stratified on matched sets, were used to estimate the RA-related risk of the primary and secondary AS outcomes. Multivariable models were adjusted for race, ethnicity, BMI, smoking status, RDCI, rurality, and health care use (number of outpatient visits and hospitalizations). Race was categorized as Black, White, other (American Indian or Alaska Native, Asian, Native Hawaiian or Pacific Islander, or multiracial), or unknown. Sensitivity analyses were performed in an incident RA cohort who received at least 365 days of care in the VHA before an RA diagnosis code was placed or DMARD dispense occurred,17 as well as among patients 65 years or older, a Medicare-age population for which we expect VHA and CMS data to have near-complete capture of events. In addition to adjusting for health care use in primary analyses, we further examined the potential for ascertainment bias by stratifying models by quartiles of outpatient visits among patients with RA.
In secondary analyses, AS risk was assessed in models stratified by seropositivity and the presence of elevated inflammatory measures at baseline. To examine temporal trends in RA-related AS risk, analyses were stratified by RA diagnosis year (2000-2005, 2006-2011, and 2012 or later) in the incident RA cohort. Among patients with RA, we evaluated risk factors for AS incorporating the above covariates and RA-related factors including seropositivity, systemic inflammation, and DMARDs (including glucocorticoids) in a multivariable Cox proportional hazards regression model. A 2-tailed P < .05 was considered statistically significant. All analyses were performed between August 23, 2022, and March 3, 2023, using Stata, Version 17 (StataCorp LLC).
The study cohort consisted of 73 070 patients with RA who were matched with 639 268 patients without RA. Patients were predominantly male (64 008 males [87.6%] and 9 062 females [12.4%] in the RA group and 554 182 males [86.7%] and 85 086 females [13.3%] in the control group; Table 1), with a mean (SD) age of 63.0 (11.9) years in the RA group and 61.9 (11.7) years in the control group. White race was predominant in both groups (52 180 patients [72.3%] and 394 531 patients [61.7%] in the control group), although information on race was more frequently missing among the control patients (129 462 patients [11.6%] with RA vs 8 498 [20.3%] in the control group). Patients with RA more frequently had ever-smoker status (80.8% vs 67.7%) and had a higher degree of comorbidity (mean [SD] RDCI, 1.7 [1.6] vs 1.2 [1.5]). A higher proportion of patients with RA vs without received an echocardiogram (51.0% vs 43.0%, standardized difference 0.16). Among patients with RA, 68.9% had seropositive test results for RF or anti-CCP and 47.0% had an elevated baseline ESR or CRP level. At baseline, most patients with RA had previously received a csDMARD (92.1%), whereas 18.7% had received a b/tsDMARD and 42.6% had received glucocorticoids.
We identified 16 109 composite AS outcomes over 6 223 150 person-years, of which 2303 occurred in patients with RA. Mean (SD) follow-up time was 7.9 (5.3) years in patients with RA and 8.8 (5.6) years in patients without RA. Most clinical AS diagnoses (79%) were identified in VHA data, whereas valvular interventions (86%) were more often identified in CMS data (eTable 2 in Supplement 1). Mean (SD) age at AS onset was similar in patients with RA (74.9 [9.7] years) and without RA (75.5 [9.1] years). Patients with RA experienced an absolute risk increase of 1.52 composite AS events per 1000 person-years (composite AS events per 1000 person-years, 3.97 [95% CI, 3.81-4.13] in patients with RA vs 2.45 [95% CI, 2.41-2.49] in control patients), which included higher rates of AS-related interventions and AS-related death (Table 2).
Risk of Composite AS Outcomes
Compared with matched control patients, patients with RA had an increased risk of the composite AS outcome (hazard ratio [HR], 1.66; 95% CI, 1.59-1.74). After adjusting for potential confounders, an increased risk of incident AS persisted (adjusted HR [AHR], 1.48; 95% CI, 1.41-1.55) (Figure). Rheumatoid arthritis was also associated with a higher risk of undergoing an AS-related valvular intervention (AHR, 1.34; 95% CI, 1.22-1.48), including SAVR (AHR, 1.30; 95% CI, 1.16-1.45) and TAVR (AHR, 1.53; 95% CI, 1.26-1.85). Patients with RA had an increased risk of death related to AS (AHR, 1.26; 95% CI, 1.04-1.54) compared with patients without RA. Aortic stenosis risk was similar in sensitivity analyses restricted to patients older than 65 years (eFigure 1 in Supplement 1) and among incident cases of RA (eFigure 2 in Supplement 1), although the risk of TAVR and AS-related death did not reach statistical significance in the incident RA cohort given the smaller sample size. The risk of AS was higher in patients with RA who had an elevated ESR or CRP level at baseline (AHR, 1.56; 95% CI, 1.44-1.70) compared with those without ESR or CRP levels elevations at baseline (HR, 1.41; 95% CI, 1.30-1.53) and among patients with seronegative results for RA autoantibodies (AHR, 1.62; 95% CI, 1.47-1.79) vs those with seropositive test results (AHR, 1.44; 95% CI, 1.35-1.54), although these differences were not statistically significant. Temporal trends in risk of the composite AS outcome was similar across RA diagnosis time periods, with AHR ranging from 1.40 (95% CI, 1.20-1.63) in 2000 to 2005 to 1.51 (95% CI, 1.27-1.80) in 2012 or later (eFigure 3 in Supplement 1). In addition, the risk of the composite AS outcome defined by outpatient health care use was similar across quartiles (AHR range, 1.31 [95% CI, 1.16-1.49] to 1.57 [95% CI, 1.43-1.64]) (eFigure 4 in Supplement 1).
AS Risk Factors in Patients With RA
Baseline characteristics of patients with RA stratified by AS development during follow-up are listed in Table 3. Age (risk quantified per 5-y increase) and BMI >30 were independently associated with a stepwise increased risk of AS (Table 4). Females and patients with Black race or Hispanic ethnicity had a lower risk of developing AS. Hypertension, stroke, and other noncoronary CVDs were associated with incident AS, whereas coronary artery disease, diabetes, and lung disease were not. Among RA-related risk factors, elevated ESR or CRP level (AHR, 1.11; 95% CI, 1.01-1.22) and baseline use of b/tsDMARDs (AHR, 1.22; 95% CI, 1.07-1.39) or glucocorticoids (AHR, 1.19; 95% CI, 1.08-1.32) were associated with a higher risk of incident AS. Seropositivity was not associated with AS development (AHR, 0.94; 95% CI, 0.86-1.04).
In this large, national cohort study that linked VHA and CMS data to maximize capture of AS diagnoses and procedures, patients with RA had an absolute risk increase of 1.52 composite AS events per 1000 person-years compared with patients without RA. Additionally, patients with RA had a higher risk for aortic valve replacement and AS-related death. These findings support those of preclinical studies depicting the role of immune and inflammatory mediators in the development of valvular carditis.4,25,26 Together, these data support the view that valvular heart disease, specifically AS, may be a CVD complication in RA.
Several studies have reported an association between CVD risk and RA, with a meta-analysis27 estimating a 1.5-to 2-fold higher risk of incident CVD, including myocardial infarction, stroke, and heart failure, in patients with RA. Despite a prevalence in the general population similar to that of heart failure,12 AS was not evaluated in that meta-analysis.27 Small, cross-sectional studies have described echocardiographic findings of calcifications, thickening, and nodules as the most common valvular abnormalities in RA.9-11 However, these studies included asymptomatic younger patients (mean ages, 47 to 51 years) without a control group or longitudinal follow-up, leaving the clinical implications of these findings unclear since AS typically affects adults older than 65 years.12 In this cohort of patients with RA (mean age, 63 years) and matched control patients followed up for more than 6 000 000 person-years, patients with RA had a 48% increased risk of AS that was independent of traditional CVD risk factors.
After linking with CMS data to capture valvular interventions performed outside the VHA, RA was associated with an increased risk of any aortic valve intervention (AHR, 1.34; 95% CI, 1.22-1.48), including both SAVR (AHR, 1.30; 95% CI, 1.16-1.45) and TAVR (AHR, 1.53; 95% CI, 1.26-1.85), suggesting a more severe AS disease course that required more frequent procedural intervention. This is of particular concern since patients with RA who underwent SAVR experienced poorer postoperative outcomes in 1 study.28 Aggregate inpatient costs per patient undergoing SAVR or TAVR exceeded $60 000 at 6 to 12 months postoperatively.18,29
We found that patients with RA had an increased risk (AHR, 1.26; 95% CI, 1.04-1.54) of AS-related death, a mortality risk similar to that of ischemic heart disease in previous RA cohorts.8,27 These data support a more severe AS disease course in contrast to a smaller study that reported similar AS progression rates in patients with RA and control patients, although that study had a shorter follow-up time and did not examine clinical AS outcomes.30 The findings from the present study emphasize that valvular heart disease may be an underrecognized contributor to the persistent CVD-related mortality gap in RA,8 particularly given the lack of improvement in AS-specific risk over time.
Mechanistic associations between RA disease activity, systemic inflammation, and CVD have been reported in several previous studies.3,31 Although valvular disease is less frequently studied than atherosclerotic CVD in this context, animal models of autoantibody-induced inflammatory arthritis have found activation of valve-resident cardiac phagocytes by circulating autoantibodies, leading to valvular carditis through the recruitment of CD4+ T-cells and macrophages.25,26 In an immunohistochemical study7 of explanted aortic valves from patients without RA but with AS, macrophage and T-cell infiltrates were found, supporting the contribution of an inflammatory process to what has been traditionally considered degenerative AS. Among the RA-related factors examined in the present study, we observed a modestly increased risk for AS among patients with RA who have elevated ESR or CRP level at baseline, suggesting that more severe RA disease activity may be associated with a higher risk of developing AS. Further supporting this finding, we observed associations between the receipt of more aggressive RA treatments, including b/tsDMARDs and glucocorticoids, with incident AS. These data were in line with results of preclinical studies4,5 suggesting that higher degrees of systemic inflammation were a risk factor for AS in patients with RA and a factor in AS progression in a prior RA cohort.30 In addition to inflammation due to RA disease activity, patients with RA are disproportionately affected by multimorbidity and metabolic syndrome, which may contribute to higher systemic inflammation and poorer AS-related outcomes.32-34 Continued research is warranted to elucidate the inflammatory pathways mediating AS risk and severity in RA cohorts.
In addition to RA-related factors, we examined traditional CVD risk factors as risk factors for AS in patients with RA. Consistent with previously reported national health statistics,12 we found that male sex and hypertension were independently associated with AS onset in patients with RA, whereas other traditional risk factors, including smoking status, diabetes, and coronary artery disease, were not. In contrast to the so-called obesity paradox in RA in which patients with underweight have a greater risk of CVD mortality compared with patients with overweight or obesity,35-38 we found that BMI ≥30 was associated with AS and AS-related death. This finding suggests a unique interaction between obesity and AS, potentially through pathways mediated by oxidized lipoproteins.39 Further study delineating the contribution of metabolic syndrome to AS-related risk in this population is warranted.
This study has limitations. While we observed an association between RA status and AS risk, the absolute risk differences were modest given the infrequency of AS-related events. Consistent with the VHA population, the cohort was predominantly male. This may limit the generalizability of the results because RA is more common in females.40 While misclassification of RA status is possible using administrative algorithms, the algorithms used had a high positive predictive value (>90%) and misclassification in this regard would bias results to the null. Similarly, misclassification of AS and AS-related death may have occurred using diagnostic codes. However, we adapted previously validated diagnostic and procedural codes and anticipated any misclassification to be nondifferential between patients with or without RA. We were unable to account for bicuspid aortic valves using diagnostic codes, which could in part explain the lower AS risk among Black patients with RA, given previous reports that bicuspid aortic valves are less common in Black patients.41 There was risk for residual confounding since we did not capture time-varying comorbidities and health behaviors as well as unmeasured confounders, such as activity intolerance, that might have led to a higher rate of testing and AS detection. As an AS diagnosis may be made on echocardiographic findings alone, a high-risk population receiving echocardiograms more often or for alternative indications (eg, ischemic heart disease, pericarditis, or cardiomyopathy) could have led to an overestimate of AS risk in patients with RA. To mitigate this risk, we leveraged national VHA data to account for several traditional CVD risk factors and adjusted for health care use (number of outpatient visits and hospitalizations). Furthermore, analyses stratified by frequency of health care use showed similar estimates for RA-related AS risk. Additionally, we observed an increased risk of aortic valve interventions, supporting the validity of the findings given the infrequency with which incidentally discovered AS requires procedural intervention. While the findings suggest a more severe AS disease course in patients with RA, we did not have data on the severity or progression of aortic valve dynamics. Although associations between AS development and elevated inflammatory markers and baseline glucocorticoid and b/tsDMARD use suggest that more severe RA may confer a higher risk of incident AS, we did not have longitudinal RA disease activity measures or medication courses to evaluate causal associations underlying these findings.
In this cohort study of VHA and CMS linked data from patients with RA who were matched with control patients, we found that patients with RA had an absolute risk increase of developing AS of 1.52 per 1000 person-years, more frequently needed aortic valve replacement, and experienced more frequent AS-related death. Future studies are needed to confirm whether valvular heart disease, specifically AS, may be an overlooked CVD complication in RA.
Accepted for Publication: May 20, 2023.
Published Online: July 31, 2023. doi:10.1001/jamainternmed.2023.3087
Corresponding Author: Bryant R. England, MD, PhD, University of Nebraska Medical Center, 986270 Nebraska Medical Center, Omaha, NE 68198-6270 (bryant.england@unmc.edu).
Author Contributions: Drs Johnson and England had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Johnson, Mahabir, Goldsweig, Cannon, Mikuls, England.
Acquisition, analysis, or interpretation of data: Johnson, Mahabir, Yang, Roul, Goldsweig, Binstadt, Baker, Sauer, Mikuls, England.
Drafting of the manuscript: Johnson, Mahabir, Goldsweig, England.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Johnson, Yang, Roul, Goldsweig.
Obtained funding: Johnson, Mikuls, England.
Administrative, technical, or material support: Johnson, Roul, Goldsweig, Sauer, Cannon, Mikuls, England.
Supervision: Johnson, Goldsweig, Baker, England.
Conflict of Interest Disclosures: Dr Johnson reported receiving grants from Rheumatology Research Foundation during the conduct of the study. Dr Goldsweig reported receiving personal fees from Edwards Lifesciences for speaking honorarium outside the submitted work. Dr Binstadt reported receiving grants from Sobi and Pfizer outside the submitted work. Dr Baker reported receiving consulting fees from CorEvitas and Cumberland Pharmaceuticals outside the submitted work. Dr Mikuls reported receiving grants from the US Department of Veterans Affairs and Horizon Therapeutics; personal fees from Horizon Therapeutics, Pfizer, and Sanofi outside the submitted work; and royalties from UpToDate and Elsevier outside the submitted work. Dr England reported receiving grants from the US Department of Veterans Affairs during the conduct of the study and personal fees from Boehringer Ingelheim outside the submitted work. No other disclosures were reported.
Funding/Support: This work was supported by the Center of Excellence for Suicide Prevention, Joint Department of Veterans Affairs, and Department of Defense Mortality Data Repository National Death Index. Dr Johnson was supported by a Rheumatology Research Foundation Scientist Development Award. Dr England was supported by the Veterans Affairs (VA) Clinical Science Research & Development (CSR&D) Service (award CX002203). Dr Mikuls was supported by the VA Biomedical Laboratory Research and Development Service (award BX004660), Department of Defense (award PR200793), National Institutes of General Medical Sciences (award U54 GM115458), and Horizon Therapeutics. Dr Baker was supported by the VA CSR&D Service (award CX001703) and VA Office of Rehabilitation Research & Development Service (award RX003644).
Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 2.
2.Sokka
T, Abelson
B, Pincus
T. Mortality in rheumatoid arthritis: 2008 update.
Clin Exp Rheumatol. 2008;26(5)(suppl 51):S35-S61.
PubMedGoogle Scholar 5.Bourgeois
R, Bourgault
J, Despres
AA,
et al. Lipoprotein proteomics and aortic valve transcriptomics identify biological pathways linking lipoprotein(a) levels to aortic stenosis.
Metabolites. 2021;11(7):459. doi:
10.3390/metabo11070459
PubMedGoogle ScholarCrossref 7.Otto
CM, Kuusisto
J, Reichenbach
DD, Gown
AM, O’Brien
KD. Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis: histological and immunohistochemical studies.
Circulation. 1994;90(2):844-853. doi:
10.1161/01.CIR.90.2.844
PubMedGoogle ScholarCrossref 8.Johnson
TM, Yang
Y, Roul
P,
et al. A narrowing mortality gap: temporal trends of cause-specific mortality in a national matched cohort study in US veterans with rheumatoid arthritis.
Arthritis Care Res (Hoboken). Published online November 4, 2022.
PubMedGoogle Scholar 9.Beckhauser
AP, Vallin
L, Burkievcz
CJ, Perreto
S, Silva
MB, Skare
TL. Valvular involvement in patients with rheumatoid arthritis.
Acta Reumatol Port. 2009;34(1):52-56.
PubMedGoogle Scholar 11.Yiu
KH, Wang
S, Mok
MY,
et al. Relationship between cardiac valvular and arterial calcification in patients with rheumatoid arthritis and systemic lupus erythematosus.
J Rheumatol. 2011;38(4):621-627. doi:
10.3899/jrheum.100844
PubMedGoogle ScholarCrossref 12.Benjamin
EJ, Virani
SS, Callaway
CW,
et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart and stroke disease statistics—2018 update: a report from the American Heart Association.
Circulation. 2018;137(12):e67-e492. doi:
10.1161/CIR.0000000000000558
PubMedGoogle ScholarCrossref 17.Curtis
JR, Xie
F, Chen
L, Greenberg
JD, Zhang
J. Evaluation of a methodologic approach to define an inception cohort of rheumatoid arthritis patients using administrative data.
Arthritis Care Res (Hoboken). 2018;70(10):1541-1545. doi:
10.1002/acr.23533
PubMedGoogle ScholarCrossref 23.Melzer
AC, Pinsker
EA, Clothier
B,
et al. Validating the use of Veterans Affairs tobacco health factors for assessing change in smoking status: accuracy, availability, and approach.
BMC Med Res Methodol. 2018;18(1):39. doi:
10.1186/s12874-018-0501-2
PubMedGoogle ScholarCrossref 25.Hobday
PM, Auger
JL, Schuneman
GR, Haasken
S, Verbeek
JS, Binstadt
BA. Fcγ receptor III and Fcγ receptor IV on macrophages drive autoimmune valvular carditis in mice.
Arthritis Rheumatol. 2014;66(4):852-862. doi:
10.1002/art.38311
PubMedGoogle ScholarCrossref 28.Malmberg
M, Palomäki
A, Sipilä
JOT, Rautava
P, Gunn
J, Kytö
V. Long-term outcomes of surgical aortic valve replacement in patients with rheumatoid arthritis.
J Clin Med. 2021;10(11):2492. doi:
10.3390/jcm10112492
PubMedGoogle ScholarCrossref 30.Bois
JP, Crowson
CS, Khullar
T, Achenbach
SJ, Krause
ML, Mankad
R. Progression rate of severity of aortic stenosis in patients with rheumatoid arthritis.
Echocardiography. 2017;34(10):1410-1416. doi:
10.1111/echo.13652
PubMedGoogle ScholarCrossref 35.Coutinho
T, Goel
K, Corrêa de Sá
D,
et al. Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data.
J Am Coll Cardiol. 2011;57(19):1877-1886. doi:
10.1016/j.jacc.2010.11.058
PubMedGoogle ScholarCrossref 37.Kremers
HM, Nicola
PJ, Crowson
CS, Ballman
KV, Gabriel
SE. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis.
Arthritis Rheum. 2004;50(11):3450-3457. doi:
10.1002/art.20612
PubMedGoogle ScholarCrossref 40.Finckh
A, Gilbert
B, Hodkinson
B,
et al. Global epidemiology of rheumatoid arthritis.
Nat Rev Rheumatol. 2022;18(10):591-602.
PubMedGoogle Scholar